Pfizer and BioNTech Test COVID-19 Vaccine in Pregnant Women

Pfizer and BioNTech announced that they have dosed the first patients in a global study evaluating their COVID-19 vaccine in pregnant women 18 years and over.

The phase 2/3 trial, which aims to address the lack of data for this population, will enroll 4,000 pregnant volunteers to assess the vaccine’s safety, tolerability and immunogenicity profile. The study is slated to last between seven to 10 months.

The Pfizer/BioNtech study will also attempt to determine if the women transfer protective antibodies to their babies, who will be monitored until six months of age.